Mode of Action (MoA) and Phase III Data

Learn about the MoA of Vyxeos Liposomal, as well as the Phase III data in high-risk* acute myeloid leukaemia (AML) patients.

Prescribing information can be found at the top of this page. Adverse event reporting is available at the bottom of this page.

Topics: Safety Vyxeos Liposomal Data

ADVERSE EVENTS REPORTING

Adverse events should be reported. Reporting forms and information for the UK can be found at https://yellowcard.mhra.gov.uk/

For Ireland, reporting forms and information can be found at: www.hpra.ie

Adverse events should also be reported to Jazz Pharmaceuticals at AEreporting@jazzpharma.com

UK-VYX-2000172 | March 2021